Electronic prescribing company DrFirst acquires VisibilityRx

With the acquisition, the 60,000 physician clients that use DrFirst can now more easily identify and refer patients to new clinical trials.
With the acquisition, the 60,000 physician clients that use DrFirst can now more easily identify and refer patients to new clinical trials. | Contributed image

DrFirst, an electronic prescribing company, has acquired VisibilityRx, a provider of clinical trial recruitment services to life sciences, clinical research organizations and pharmacies.

"We are excited to welcome VisibilityRx to the DrFirst family and create new opportunities to advance patient participation in the clinical trial process," G. Cameron Deemer, president of DrFirst, said in a statement. "The acquisition delivers an existing client base and experienced management and provides us with a comprehensive solution that addresses a need for so many patients, physicians, pharmacies and clinical research organizations. This platform will enhance the value of our partners' electronic health record and pharmacy products, while also helping providers deliver the newest and most applicable clinical trial information to their patients."

Through the acquisition, the 60,000 physician clients that use DrFirst can now more easily identify and refer patients to new clinical trials.

"Coordinated communications at the point of care and throughout the patient's prescription experience are essential in the patient care process," Joe Rector, president of VisibilityRx, said. "An additional benefit of VisibilityRx is that it provides DrFirst's life sciences partners new points of engagement during the patient's prescription lifetime, enabling them to reinforce critical information with patients.”